litlas
ログインアカウント作成

Michael Grundman

1986–2026 年に発表

73
論文数
23,668
被引用数
58
h 指数
70
i10 指数

被引用数

Michael Grundman の年別被引用数1987 年: 被引用 2 件1988 年: 被引用 5 件1989 年: 被引用 2 件1990 年: 被引用 4 件1991 年: 被引用 5 件1992 年: 被引用 7 件1993 年: 被引用 7 件1994 年: 被引用 4 件1995 年: 被引用 5 件1996 年: 被引用 6 件1997 年: 被引用 12 件1998 年: 被引用 47 件1999 年: 被引用 55 件2000 年: 被引用 116 件2001 年: 被引用 159 件2002 年: 被引用 171 件2003 年: 被引用 153 件2004 年: 被引用 206 件2005 年: 被引用 234 件2006 年: 被引用 276 件2007 年: 被引用 252 件2008 年: 被引用 274 件2009 年: 被引用 218 件2010 年: 被引用 325 件2011 年: 被引用 342 件2012 年: 被引用 310 件2013 年: 被引用 331 件2014 年: 被引用 364 件2015 年: 被引用 299 件2016 年: 被引用 303 件2017 年: 被引用 276 件2018 年: 被引用 292 件2019 年: 被引用 709 件2020 年: 被引用 721 件2021 年: 被引用 707 件2022 年: 被引用 622 件2023 年: 被引用 508 件2024 年: 被引用 694 件2025 年: 被引用 399 件2026 年: 被引用 13 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,557 件、この内訳の 31.5%イギリス: 引用元論文 993 件、この内訳の 8.8%中国: 引用元論文 633 件、この内訳の 5.6%ドイツ: 引用元論文 543 件、この内訳の 4.8%カナダ: 引用元論文 490 件、この内訳の 4.3%イタリア: 引用元論文 475 件、この内訳の 4.2%オーストラリア: 引用元論文 390 件、この内訳の 3.5%フランス: 引用元論文 371 件、この内訳の 3.3%スウェーデン: 引用元論文 356 件、この内訳の 3.1%スペイン: 引用元論文 325 件、この内訳の 2.9%オランダ: 引用元論文 315 件、この内訳の 2.8%日本: 引用元論文 258 件、この内訳の 2.3%
0%31.5%その他 22.9%

機関

分野

  • Medicine72.2%
  • Neuroscience11.5%
  • Biochemistry, Genetics and Molecular Biology7.6%
  • Computer Science1.6%
  • Psychology1.5%
  • Nursing1%
  • その他4.6%

トピック

  • Alzheimer's disease research and treatments16.6%
  • Dementia and Cognitive Impairment Research12%
  • Cholinesterase and Neurodegenerative Diseases4.5%
  • Neuroinflammation and Neurodegeneration Mechanisms3.1%
  • Computational Drug Discovery Methods2.6%
  • Parkinson's Disease Mechanisms and Treatments2.6%
  • その他58.6%

共著者

全論文

検索で開く
  1. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

    著者: Stephen Salloway, Reisa A. Sperling, Nick C. Fox, Kaj Blennow, William E. Klunk, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Anton P. Porsteinsson, Steven H. Ferris, Marcel Reichert, Nzeera Ketter, Bijan Nejadnik, Volkmar Guenzler, Maja Miloslavsky, Daniel Wang, Yuan Lü, Julia Lull, Iulia Cristina Tudor, Enchi Liu, Michael Grundman, Eric Yuen, Ronald S. Black, H. Robert Brashear - New England Journal of Medicine 2014 被引用: 1,965

  2. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

    著者: Reisa A. Sperling, Clifford R. Jack, Sandra E. Black, Matthew P. Frosch, Steven M. Greenberg, Bradley T. Hyman, Philip Scheltens, María C. Carrillo, William Thies, Martin M. Bednar, Ronald S. Black, H. Robert Brashear, Michael Grundman, Eric Siemers, Howard Feldman, Rachel Schindler - Alzheimer s & Dementia 2011 被引用: 830

  3. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

    著者: Reisa A. Sperling, Stephen Salloway, David J. Brooks, Donatella Tampieri, Jerome Barakos, Nick C. Fox, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Anton P. Porsteinsson, Ivan Lieberburg, H. Michael Arrighi, Kristen Morris, Yuan Lü, Enchi Liu, Keith M. Gregg, H. Robert Brashear, Gene G. Kinney, Ronald S. Black, Michael Grundman - The Lancet Neurology 2012 被引用: 510

  4. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

    著者: the Synaptic Health Endpoints Working Group, Martí Colom‐Cadena, Tara L. Spires‐Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John Harrison, Lon S. Schneider, Philip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo, Susan M. Catalano - Alzheimer s Research & Therapy 2020 被引用: 355

  5. Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs

    著者: Richard C. Mohs, David S. Knopman, Ronald C. Petersen, Steven H. Ferris, Chris Ernesto, Michael Grundman, Mary Sano, Linas A. Bieliauskas, David Geldmacher, Chris M. Clark, Leon J. Thal - Alzheimer Disease & Associated Disorders 1997 被引用: 703

  6. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease

    著者: Douglas Galasko, David A. Bennett, Mary Sano, Chris Ernesto, Ronald J. Thomas, Michael Grundman, Steven H. Ferris - Alzheimer Disease & Associated Disorders 1997 被引用: 1,193

  7. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

    著者: Joseph Jankovic, Ira Goodman, Beth Safirstein, Tonya Marmon, Dale B. Schenk, Martin Koller, Wagner Zago, Daniel Ness, Sue G. Griffith, Michael Grundman, Jay Soto, Susanne Ostrowitzki, Frank Boess, Meret Martin‐Facklam, Joseph F. Quinn, Stuart Isaacson, Omid Omidvar, Aaron Ellenbogen, Gene G. Kinney - JAMA Neurology 2018 被引用: 292

  8. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

    著者: Tien Dam, Adam L. Boxer, Lawrence I. Golbe, Günter U. Höglinger, Huw R. Morris, Irene Litvan, Anthony E. Lang, Jean‐Christophe Corvol, Ikuko Aiba, Michael Grundman, Lili Yang, Beth Tidemann‐Miller, Joseph Kupferman, Kristine D. Harper, Kubra Kamisoglu, Michael Wald, Danielle Graham, Liz Gedney, John O’Gorman, Samantha Budd Haeberlein, PASSPORT Study Group - Nature Medicine 2021 被引用: 138

  9. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

    著者: Ronald Petersen, Ronald G. Thomas, Michael Grundman, David Bennett, Rachelle S. Doody, Steven H. Ferris, Douglas Galasko, Shelia Jin, Jeffrey Kaye, Allan I. Levey, Eric Pfeiffer, Mary Sano, Christopher H. van Dyck, Leon J. Thal - New England Journal of Medicine 2005 被引用: 1,858

  10. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

    著者: Stephen Salloway, Reisa A. Sperling, S. Gilman, Nick C. Fox, Kaj Blennow, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Rachelle S. Doody, Christopher H. van Dyck, Ruth A. Mulnard, Jerome Barakos, K. M. Gregg, E. Liu, Ivan Lieberburg, Dale Schenk, Ronald S. Black, Michael Grundman - Neurology 2009 被引用: 739

  11. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

    著者: Richard C. Mohs, David S. Knopman, R. Petersen, Steven H. Ferris, Christopher Ernesto, Michael Grundman, Mary Sano, Linas A. Bieliauskas, David Geldmacher, Camilla N. Clark, L. J. Thal - 1997 被引用: 493

  12. Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial

    著者: Florian Lipsmeier, Kirsten I. Taylor, Timothy Kilchenmann, Detlef Wolf, Alf Scotland, Jens Schjodt‐Eriksen, Wei‐Yi Cheng, Ignacio Fernandez‐Garcia, Juliane Siebourg‐Polster, Liping Jin, Jay Soto, Lynne Verselis, Frank Boess, Martin Koller, Michael Grundman, Andreas U. Monsch, Ronald B. Postuma, Anirvan Ghosh, Thomas Kremer, Christian Czech, Christian Gossens, Michael Lindemann - Movement Disorders 2018 被引用: 268

  13. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

    著者: Mary Sano, Christopher Ernesto, Ronald G. Thomas, Melville R. Klauber, Kimberly Schafer, Michael Grundman, Peter Woodbury, John H. Growdon, Carl W. Cotman, Eric Pfeiffer, Lon S. Schneider, Leon J. Thal - New England Journal of Medicine 1997 被引用: 2,383

  14. First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

    著者: Dale B. Schenk, Martin Koller, Daniel Ness, Sue G. Griffith, Michael Grundman, Wagner Zago, Jay Soto, George Atiee, Susanne Ostrowitzki, Gene G. Kinney - Movement Disorders 2016 被引用: 248

  15. Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials

    著者: Michael Grundman - Archives of Neurology 2004 被引用: 971

  16. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease

    著者: Joseph L. Price, Daniel W. McKeel, Virginia Buckles, Catherine M. Roe, Chengjie Xiong, Michael Grundman, Lawrence A. Hansen, Ronald C. Petersen, Joseph E. Parisi, Dennis W. Dickson, Charles D. Smith, Daron G. Davis, Frederick A. Schmitt, William R. Markesbery, Jeffrey Kaye, Roger Kurlan, Christine Hulette, Brenda F. Kurland, Roger Higdon, Walter A. Kukull, John C. Morris - Neurobiology of Aging 2009 被引用: 656

  17. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

    著者: Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera, Colleen S. Limegrover, Courtney Rehak, Raymond Yurko, Lora Waybright, Gary C. Look, Gilbert M. Rishton, Hank Safferstein, Mary E. Hamby, Claire Williams, Kelsey Sadlek, Hannah M. Edwards, Charles S. Davis, Michael Grundman, Lon S. Schneider, Steven T. DeKosky, Daniel Chelsky, Ian Pike, Christopher M. Henstridge, Kaj Blennow, Henrik Zetterberg, Harry LeVine, Tara L. Spires‐Jones, John R. Cirrito, Susan M. Catalano - Alzheimer s & Dementia 2021 被引用: 103

  18. MR Imaging Features of Amyloid-Related Imaging Abnormalities

    著者: Jerome Barakos, Reisa A. Sperling, Stephen Salloway, Clifford R. Jack, Achim Gass, Jochen B. Fiebach, Donatella Tampieri, D Melançon, Y Miaux, Gregory A. Rippon, Ronald S. Black, Yuan Lü, H. Robert Brashear, H. Michael Arrighi, Kristen Morris, Michael Grundman - American Journal of Neuroradiology 2013 被引用: 111

  19. Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases

    著者: Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, Anthony O. Caggiano, Michael Grundman, Mary E. Hamby - International Journal of Molecular Sciences 2023 被引用: 46

  20. A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

    著者: Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, Weihua Zhao, David R. Beers, Maria B. Pascual, Mohammad Obadah Nakawah, Gustavo C. Román, Charles S. Davis, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel - Translational Neurodegeneration 2023 被引用: 38

  21. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

    著者: Paul Aisen, Kimberly Schafer, Michael Grundman, Eric Pfeiffer, Mary Sano, Kenneth L. Davis, Martin R. Farlow, Shelia Jin, Ronald G. Thomas, Leon J. Thal - 2003 被引用: 968

  22. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

    著者: Juha O. Rinne, David J. Brooks, Martin N. Rossor, Nick C. Fox, Roger Bullock, William E. Klunk, Chester A. Mathis, Kaj Blennow, Jerome Barakos, Aren Okello, Sofia Rodriguez Martinez de Liano, Enchi Liu, Martin Koller, Keith M. Gregg, Dale Schenk, Ronald S. Black, Michael Grundman - The Lancet Neurology 2010 被引用: 695

  23. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

    著者: Adam L. Boxer, Irfan Qureshi, Michael K. Ahlijanian, Michael Grundman, Lawrence I. Golbe, Irene Litvan, Lawrence S. Honig, Paul Tuite, Nikolaus R. McFarland, Padraig O’Suilleabhain, Tao Xie, Giridhar Tirucherai, Clifford Bechtold, Yvette Bordelon, David Geldmacher, Murray Grossman, Stuart Isaacson, Theresa Zesiewicz, Tina M. Olsson, Kumar Kandadi Muralidharan, Danielle Graham, John O’Gorman, Samantha Budd Haeberlein, Tien Dam - The Lancet Neurology 2019 被引用: 141

  24. A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

    著者: Ronald S. Black, Reisa A. Sperling, Beth Safirstein, Ruth Motter, Allan Pallay, Alice I. Nichols, Michael Grundman - Alzheimer Disease & Associated Disorders 2010 被引用: 168